Status:
RECRUITING
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Collaborating Sponsors:
Juventas Cell Therapy Ltd.
Conditions:
Acute Lymphoblastic Leukemia ALL
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy o...
Detailed Description
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy o...
Eligibility Criteria
Inclusion
- Adult patients with high-risk acute B-lymphoblastic leukemia
- Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
- Eligible for autologous hematopoietic stem cell transplantation
- No major organ dysfunction
Exclusion
- Combined with malignant tumors of other organs
- With a serious infection that is not under control
- Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive
- Patients who have had an allergic reaction to the drugs used in this study or similar drugs
- Other patients deemed unsuitable for inclusion by the investigators
Key Trial Info
Start Date :
June 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2028
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06608342
Start Date
June 25 2024
End Date
May 30 2028
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NO.288 Nanjing Road，Heping District，Tianjin, Tianjin,
Tianjin, Tianjin Municipality, China, 300000